推荐产品
形狀
solid
品質等級
顏色
white
溶解度
methanol: >10 mg/mL
H2O: insoluble
SMILES 字串
O.Cl.COc1ccccc1N2CCN(CC2)CC(O)COc3cccc4ccccc34
InChI
1S/C24H28N2O3.ClH.H2O/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23;;/h2-12,20,27H,13-18H2,1H3;1H;1H2
InChI 密鑰
INIDYCYXDNFBSV-UHFFFAOYSA-N
基因資訊
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)
生化/生理作用
α1-Adrenoceptor antagonist; antihypertensive.
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
International journal of urology : official journal of the Japanese Urological Association, 18(3), 225-230 (2011-01-29)
The aim of the present study was to explore the effects of three different types of alpha-1 adrenoceptor blockers (α1-blocker) on lower urinary tract symptoms (LUTS), erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in patients with benign prostatic hyperplasia. A
Anticancer research, 33(3), 887-894 (2013-03-14)
Naftopidil, an α1-adrenoceptor blocker, has been clinically used for the treatment of benign prostate hyperplasia and hypertension. Emerging evidence has shown that naftopidil exhibits an antitumor effect on a variety of cancer types including prostate cancer. The aim of the
Hinyokika kiyo. Acta urologica Japonica, 57(1), 7-13 (2011-02-10)
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50
International journal of urology : official journal of the Japanese Urological Association, 18(11), 792-795 (2011-09-16)
The aim of the present study was to compare the efficacy of the selective α(1D) -adrenoceptor antagonist naftopidil and the selective α(1A) -adrenoceptor antagonist silodosin (as an example) in the management of ureteral stones in Japanese male patients. A total
International journal of radiation oncology, biology, physics, 81(4), e385-e392 (2011-06-15)
To compare the efficacy of three α(1A)/α(1D)-adrenoceptor (AR) antagonists--naftopidil, tamsulosin, and silodosin--that have differing affinities for the α(1)-AR subtypes in treating urinary morbidities in Japanese men with (125)I prostate implantation (PI) for prostate cancer. This single-institution prospective randomized controlled trial
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门